CAR-T-Zellen und bispezifische Antikörper: neue Optionen für Non-Hodgkin-Lymphome

Binnen weniger Jahre hat sich das therapeutische Arsenal gegen Non-Hodgkin-Lymphome drastisch verändert. Mit mehreren Zulassungen sind CAR-T-Zellen und bispezifische Antikörper mittlerweile fester Bestandteil der Therapie rezidivierter oder refraktärer Fälle. In Zukunft werden sich die Indikationen aller Wahrscheinlichkeit nach weiter ausdehnen und unter Umständen teilweise sogar die Erstlinie erreichen.

Schlüsselwörter

diffuses großzelliges B-Zell-Lymphom - follikuläres Lymphom - Non-Hodgkin-Lymphom - CAR-T-Zellen - bispezifische Antikörper

Publication History

Article published online:
02 December 2024

• Literatur

• 1 Gisselbrecht C, Glass B, Mounier N. et al. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. J Clin Oncol 2010; 28: 4184-4190
• 2 Neelapu Sattva S, Locke Frederick L, Bartlett Nancy L. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377: 2531-2544
• 3 Schuster Stephen J, Bishop Michael R, Tam Constantine S. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45-56
• 4 Abramson JS, Palomba ML, Gordon LI. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet 2020; 396: 839-852
• 5 Neelapu SS, Jacobson CA, Ghobadi A. et al. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood 2023; 141 (19) 2307-2315
• 6 Bethge WA, Martus P, Schmitt M. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 2022; 140: 349-358
• 7 Jo T, Yoshihara S, Okuyama Y. et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol 2023; 202: 256-266
• 8 Bishop MR, Dickinson M, Purtill D. et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 2022; 386: 629-639
• 9 Locke Frederick L, Miklos David B, Jacobson Caron A. et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022; 386: 640-654
• 10 Abramson JS, Solomon SR, Arnason J. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023; 141: 1675-1684
• 11 Dickinson MJ, Carlo-Stella C, Morschhauser F. et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2022; 387: 2220-2231
• 12 Thieblemont C, Phillips T, Ghesquieres H. et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol Off J Am Soc Clin Oncol 2023; 41: 2238-2247
• 13 Casulo C, Byrtek M, Dawson KL. et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol Off J Am Soc Clin Oncol 2015; 33: 2516-2522
• 14 Fowler NH, Dickinson M, Dreyling M. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022; 28: 325-332
• 15 Jacobson CA, Chavez JC, Sehgal AR. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23: 91-103
• 16 Budde LE, Sehn LH, Matasar M. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 2022; 23: 1055-1065
• 17 Wang Michael, Munoz Javier, Goy Andre. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020; 382: 1331-1342
• 18 Bücklein VL, Bader P, Bargou R. et al. CAR-T Zellen: Management von Nebenwirkungen. Onkopedia. 2020 Accessed April 27, 2024 at: https://www.onkopedia.com/de/onkopedia/guidelines/car-t-zellen-management-von-nebenwirkungen
• 19 Rejeski K, Subklewe M, Aljurf M. et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023; 142: 865-877
• 20 Wat J, Barmettler S. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. J Allergy Clin Immunol Pract 2022; 10: 460-466
• 21 Suran M. FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers. JAMA 2024; 331: 818-820
• 22 Ghilardi G, Fraietta JA, Gerson JN. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 2024; 30: 984-989
• 23 Neelapu SS, Dickinson M, Munoz J. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 2022; 28: 735-742
• 24 Westin J, Jacobson CA, Chavez JC. et al. ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. J Clin Oncol 2023; 41: TPS7578-TPS7578
• 25 Sehgal A, Hoda D, Riedell PA. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 2022; 23: 1066-1077
• 26 Shah N, Maziarz R, Jacobson C. et al. P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY. HemaSphere 2023; 7: e07109dc
• 27 Bachmann M. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett 2019; 211: 13-22
• 28 Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells – new therapeutic opportunities in hematology?. Front Immunol 2022; 13: 1034707
• 29 Mody H, Sutaria DS, Miles D. Clinical Pharmacology Considerations for the „Off-the-Shelf“ Allogeneic Cell Therapies. Clin Pharmacol Ther 2024;
• 30 Nastoupil L, Morschhauser F, Scholz CW. et al. P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere 2022; 6: 1015-1016
• 31 Falchi L, Offner F, Belada D. et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update. J Clin Oncol 2022; 40: 7523-7523
• 32 Tapia-Galisteo A, Álvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol OncolJ Hematol Oncol 2023; 16: 83
• 33 Ran T, Eichmüller SB, Schmidt P. et al. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer 2020; 147: 3438-3445